Stockreport

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA [Yahoo! Finance]

Legend Biotech Corporation - American Depositary Shares  (LEGN) 
PDF in an oral presentation at the 2024 ASCO Annual Meeting show deep and durable responses with one-time infusion of CARVYKTI ® Subgroup analysis from the CARTITUDE-4 stu [Read more]